miR-21: a non-specific biomarker of all maladies

被引：177
作者：
Jenike, Ana E. [1 ]
Halushka, Marc K. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Ross Bldg Rm 632B,720 Rutland Ave, Baltimore, MD 21205 USA
来源：
BIOMARKER RESEARCH | 2021年 / 9卷 / 01期
基金：
美国国家卫生研究院;
关键词：
microRNA; miR-21-5p; Biomarker; Plasma; Serum; cancer; Heart disease;
D O I：
10.1186/s40364-021-00272-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequently claimed to be a biomarker of diseases such as cancer and heart disease in bodily-fluid based miRNA studies. Here we dissociate its contributions to cellular physiology and pathology from its potential as a biomarker. We show how it has been claimed as a specific predictive or prognostic biomarker by at least 29 diseases. Thus, it has no specificity to any one disease. As a result, it should not be considered a viable candidate to be a biomarker, despite its continued evaluation as such. This theme of multiple assignments of a miRNA as a biomarker is shared with other common, ubiquitous miRNAs and should be concerning for them as well.
引用
收藏
页数：7
相关论文
共 82 条
[1]  
Aalami AH, BIOMARKERS, P1
[2]   Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia [J].
Abd-El-Fattah, Amal A. ;
Sadik, Nermin Abdel Hamid ;
Shaker, Olfat Gamil ;
Aboulftouh, Mariam Lotfy .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2013, 67 (03) :875-884
[3]   Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer [J].
Abue, Makoto ;
Yokoyama, Misa ;
Shibuya, Rie ;
Tamai, Keiichi ;
Yamaguchi, Kazunori ;
Sato, Ikuro ;
Tanaka, Nobuyuki ;
Hamada, Shin ;
Shimosegawa, Tooru ;
Sugamura, Kazuo ;
Satoh, Kennichi .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (02) :539-547
[4]   Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer [J].
Agaoglu, Fulya Yaman ;
Kovancilar, Muge ;
Dizdar, Yavuz ;
Darendeliler, Emin ;
Holdenrieder, Stefan ;
Dalay, Nejat ;
Gezer, Ugur .
TUMOR BIOLOGY, 2011, 32 (03) :583-588
[5]   Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma [J].
Allen-Rhoades, Wendy ;
Kurenbekova, Lyazat ;
Satterfield, Laura ;
Parikh, Neha ;
Fuja, Daniel ;
Shuck, Ryan L. ;
Rainusso, Nino ;
Trucco, Matteo ;
Barkauskas, Donald A. ;
Jo, Eunji ;
Ahern, Charlotte ;
Hilsenbeck, Susan ;
Donehower, Lawrence A. ;
Yustein, Jason T. .
CANCER MEDICINE, 2015, 4 (07) :977-988
[6]   Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer [J].
Asaga, Sota ;
Kuo, Christine ;
Nguyen, Tung ;
Terpenning, Marilou ;
Giuliano, Armando E. ;
Hoon, Dave S. B. .
CLINICAL CHEMISTRY, 2011, 57 (01) :84-91
[7]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[8]   Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma [J].
Bihrer, Verena ;
Waidmann, Oliver ;
Friedrich-Rust, Mireen ;
Forestier, Nicole ;
Susser, Simone ;
Haupenthal, Joerg ;
Welker, Martin ;
Shi, Ying ;
Peveling-Oberhag, Jan ;
Polta, Andreas ;
von Wagner, Michael ;
Radeke, Heinfried H. ;
Sarrazin, Christoph ;
Trojan, Joerg ;
Zeuzem, Stefan ;
Kronenberger, Bernd ;
Piiper, Albrecht .
PLOS ONE, 2011, 6 (10)
[9]   Serum miR-21 Expression in Human Esophageal Squamous Cell Carcinomas [J].
Cai, Er-Hui ;
Gao, Yong-Xin ;
Wei, Zhong-zhi ;
Chen, Wei-Ying ;
Yu, Ping ;
Li, Ke .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (04) :1563-1567
[10]   The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer [J].
Chan, John K. ;
Blansit, Kevin ;
Kiet, Tuyen ;
Sherman, Alexander ;
Wong, Gabriel ;
Earle, Christine ;
Bourguignon, Lilly Y. W. .
GYNECOLOGIC ONCOLOGY, 2014, 132 (03) :739-744
123456789